IN2014MU01042A - - Google Patents

Download PDF

Info

Publication number
IN2014MU01042A
IN2014MU01042A IN1042MU2014A IN2014MU01042A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A IN 1042MU2014 A IN1042MU2014 A IN 1042MU2014A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A
Authority
IN
India
Prior art keywords
compositions
component
relates
dabigatran
patients
Prior art date
Application number
Inventor
Sushrut Krishnaji Kulkarni
Ajaykumar Handa
Sagar Jugalkishor Baheti
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN1042MU2014 priority Critical patent/IN2014MU01042A/en
Priority to PCT/IN2015/000142 priority patent/WO2015145462A1/en
Publication of IN2014MU01042A publication Critical patent/IN2014MU01042A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising a first component comprising dabigatran or a pharmaceutically acceptable salt thereof in the form of a tablet and a second component comprising an organic acid. The invention also relates to processes for the preparation of such compositions and using those compositions to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IN1042MU2014 2014-03-26 2015-03-26 IN2014MU01042A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN1042MU2014 IN2014MU01042A (en) 2014-03-26 2015-03-26
PCT/IN2015/000142 WO2015145462A1 (en) 2014-03-26 2015-03-26 Pharmaceutical compositions of dabigatran

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1042MU2014 IN2014MU01042A (en) 2014-03-26 2015-03-26

Publications (1)

Publication Number Publication Date
IN2014MU01042A true IN2014MU01042A (en) 2015-10-02

Family

ID=54194086

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1042MU2014 IN2014MU01042A (en) 2014-03-26 2015-03-26

Country Status (2)

Country Link
IN (1) IN2014MU01042A (en)
WO (1) WO2015145462A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103945A1 (en) * 2015-12-15 2017-06-22 Strides Shasun Limited Pharmaceutical compositions
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
TR201617984A2 (en) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN
WO2019004980A2 (en) 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
TR201706848A2 (en) 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING DABIGATRAN ETEXCLATE
TR201722323A2 (en) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral pharmaceutical compositions of dabigatran
TR201722630A2 (en) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
TR201905308A2 (en) * 2019-04-09 2020-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A CAPSULE FORMULATION OF DABIGATRAN ETEXILATE
WO2025046547A1 (en) * 2023-09-01 2025-03-06 Glenmark Pharmaceuticals Limited A stable solid oral dosage form of dabigatran

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
JP3716901B2 (en) 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 Cellulose ether film
ES2380704T3 (en) 2002-03-07 2012-05-17 Boehringer Ingelheim International Gmbh 3 - [(2 - {[4- (Hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazol-5-carb3onyl) -pyridin-2-yl-acid methanesulfonate amino] -propionic
DE10337697A1 (en) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
US20130052262A1 (en) 2010-03-01 2013-02-28 Sandra Brueck Dabigatran etexilate-containing oral pharmaceutical composition
WO2013110567A1 (en) 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
AU2013224146B2 (en) 2012-02-21 2017-06-08 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate

Also Published As

Publication number Publication date
WO2015145462A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
IN2014MU01042A (en)
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
EP3206706A4 (en) Stable injectable composition of pharmaceutically active agents and process for its preparation
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
EP3295952A4 (en) Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
ZA201605379B (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
IL260766B (en) Continuous complexation of active pharmaceutical ingredients
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
EP3347022A4 (en) Pharmaceutical composition including dutasteride and capsule formulation comprising the same
EP3158998A4 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2017014776A (en) Pharmaceutical combination of everolimus with dactolisib.
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
IL280389A (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
EP3219311A4 (en) Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof
IL261929B (en) Stable pharmaceutical compositions for topical administration and uses thereof
ZA201901004B (en) High drug loaded tablet composition for treating hiv
IL257689B (en) Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
NZ727876A (en) Misoprostol dispersible tablet
WO2015126151A3 (en) Composition for wound healing comprising massa medicata fermentata extract
IN2013MU02585A (en)
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof